In a surprising turn of events, Adobe (Nasdaq:ADBE) and Figma announced the mutual termination of their previously announced merger agreement, initially slated for a mix of cash and stock consideration and announced in September 2022. Regulatory Hurdles Halt the Acquisition Both companies, while believing in the merger’s procompetitive benefits, have determined that there is no […]
Pfizer Inc. has announced a significant development in the treatment of multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. The European Commission (EC) has granted conditional marketing authorization for ELREXFIO (elranatamab), a targeted immunotherapy designed for adult patients with relapsed and refractory multiple myeloma (RRMM) who have received at […]
Takeda has announced a significant advancement in the treatment of Hereditary Angioedema (HAE), with the European Commission’s approval of TAKHZYRO (lanadelumab) for routine prevention in patients aged 2 years and older. This approval marks the first long-term prophylactic HAE treatment available in the European Economic Area for patients under six years of age, broadening the […]
ViiV Healthcare, majorly owned by GSK with Pfizer and Shionogi as shareholders, announced that the European Commission (EC) has authorized Apretude, also known as cabotegravir long-acting (LA) injectable and tablets, for HIV prevention. This revolutionary treatment is now the only approved HIV prevention option in the European Union that offers an alternative to 365 daily […]
In a calamitous turn of events, Slovenia grapples with its most severe flooding disaster ever recorded, claiming the lives of six individuals and leaving massive destruction in its wake. Torrential downpours have given rise to this **nightmare scenario**, where homes are being swallowed by the surging waters, villages find themselves inundated with debris, and the […]
Soliris (eculizumab), the first and only targeted therapy approved for the treatment of paediatric patients with refractory generalised myasthenia gravis (gMG), from Alexion, AstraZeneca Rare Disease has obtained approval for expanded use in the European Union (EU). The approval allows the treatment of gMG in children and adolescents aged six to 17 years who are […]
In a significant advancement for cancer treatment, the European Commission (EC) has approved Gilead Sciences’ Trodelvy (sacituzumab govitecan) for the treatment of adult patients suffering from unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have undergone endocrine-based therapy, and at least two more systemic therapies in the advanced phase. This medication is now […]
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended approval for gefapixant, an investigational, non-narcotic, oral selective P2X3 receptor antagonist from Merck, also known as MSD outside the United States and Canada. The drug is being developed for adults with refractory or unexplained chronic cough. The European Commission (EC) […]
The Menarini Group and its subsidiary, Stemline Therapeutics Inc., have received a favorable opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) regarding the approval of ORSERDU (elacestrant) monotherapy. This treatment is intended for postmenopausal women and men with estrogen receptor (ER)-positive, HER2-negative, locally advanced or metastatic breast cancer […]
The European Commission has given Broadcom, a leading global technology firm specializing in semiconductor and infrastructure software solutions, conditional approval to proceed with its acquisition of VMware. This approval from the Commission is a recognition of the acquisition’s potential to stimulate growth in the multi-cloud ecosystem, broaden customer choices, and fuel innovation and competition. Broadcom […]